Lipid Matters

An exciting series of insights and discoveries in lipid science, brought to you by a diverse line-up of contributors! Dive into our blog for fresh takes on ground-breaking publications and thought-provoking items that push the boundaries of lipid research.

25th November 2025

Potential Treatment Avenue on the Horizon for Neimann-Pick Disease Type A?

We have known for some time that Niemann-Pick Disease (NPD) is a genetic disorder that leads to fat accumulation is various tissues such as liver, spleen, and brain. When I asked folks about NPD, it is common for me to hear that lysosomal cholesterol transporters are defective in this disease. Actually, there are three major types of NPD designated as Types A, B, and C, with Type C involving the defective lysosomal cholesterol transporters designated NPC1 and NPC2. The genetic defect in Types A and B, however, appears to involve dysfunctional acid sphingomyelinases (aSMases), encoded by SMPD1 gene, which hydrolyze ceramide as well as phosphatidylcholine. The difference between NPD-A and NPD-B is that the mutation leading to NPD-A leads to a near-complete loss of SMase activity, while enzyme mutations leading to NPD-B retains some modest activity. These mutations are significant to patient outcomes as those with NPD-A rarely live more than 3 years of age, while those with NPD-B may live to adolescence or early adulthood without serious neurological difficulties. In a recent paper by Beard et al. (Neurobiol Dis 2025 Nov:216:107147) generated a mouse model in which mice harbored a S505A mutation (aSMaseS505A), which corresponds to the S507A mutation in humans retained L-SMase activity and tissue sphingomyelin levels in the brain. Interestingly however, these mice lacked S-SMase activity in serum. ASMaseS505A mice also also protected from NPD physiology and pathophysiology responses. Importantly, aSMase−/− mice that showed significant decreased locomotor control, was prevented in aSMaseS505A mice. The authors suggest that their results suggest that expression of L-SMase may serve to pave the way for enzyme replacement therapy in humans with in NPD.

Dan M. Raben

The John Hopkins University School of Medicine, Baltimore, MD, USA

Archive

2025
2024
2023

Go to older Lipid Matters posts Bill Christie's occasional series of notes on publications or other items dealing with lipid science. For the previous curated collection of comments from the world of lipid research please visit - Lipid Trends